

CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER

20-386/S-028

Approval Letter(s)



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 20-386/S-028

Merck & Co., Inc.
Attention: Michael C. Elia, Ph.D.
Sumneytown Pike
P.O. Box 4, BLA-20
West Point, PA 19486

AP Letter
= LABELING

Dear Dr. Elia:

Please refer to your supplemental new drug application dated November 9, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Cozaar (losartan potassium) 25, 50 and 100 mg Tablets.

We acknowledge receipt of your submissions dated May 14 and June 6, and September 4, 2002. Your submission of September 4, 2002 constituted a complete response to our May 10, 2002 approvable letter.

This supplemental new drug application provides for the use of Cozaar (losartan potassium) 25, 50 and 100 mg Tablets for the treatment of type 2 diabetic nephropathy.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the submitted final printed labeling (package insert included in your submission of September 4, 2002). Accordingly, the supplemental application is approved effective on the date of this letter.

Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 FR 66632). We acknowledge your request of November 9, 2001 asking for a waiver of the pediatric study requirement for this new indication. We agree to waive the pediatric study requirement for this action on this application.

Please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please send one copy to the Division of Cardio-Renal Drug Products and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

Food and Drug Administration
Rockville MD 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please contact:

Mr. Edward Fromm
Regulatory Health Project Manager
(301) 594-5332

Sincerely,


{See appended electronic signature page}

Robert Temple, M.D.
Director
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosed Labeling Text

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Robert Temple
9/17/02 02:51:36 PM

CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER

20-386/S-028

Approvable Letter



NDA 20-386/S-028

Merck & Co. Inc.
Attention: Michael C. Elia, Ph.D.
Sumneytown Pike
P.O. Box 4, BLA-20
West Point, PA 19486

Dear Dr. Elia:

Please refer to your supplemental new drug application dated November 9, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Cozaar (losartan potassium) 25, 50 and 100 mg Tablets.

We acknowledge receipt of your submissions dated December 4 and 20, 2001; January 28 and 30, February 4, 11 (two), 15 and 20, March 8, 12, 13, 22 (two) and 29, April 1, 4 and 19 (two), May 1 (two) and 6, 2002.

This supplemental new drug application proposes a new use of Cozaar (losartan potassium) 25, 50 and 100 mg Tablets for the treatment of type 2 diabetic nephropathy.

We have completed the review of this application, as amended, and it is approvable. Before this application may be approved, however, it will be necessary for you to submit final printed labeling (FPL) for the drug. The labeling should be identical in content to the enclosed labeling (text for the package insert).

In addition, all previous revisions as reflected in the most recently approved labeling must be included. To facilitate review of your submission, please provide a highlighted or marked-up copy that shows the changes that are being made.

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL, ten of which individually mounted on heavy weight paper or similar material.

If additional information relating to the safety or effectiveness of this drug becomes available, revision of the labeling may be required.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please send one copy to the Division of Cardio-Renal Drug Products and two copies of both the

promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

Within 10 days after the date of this letter, you are required to amend the supplemental application, notify us of your intent to file an amendment, or follow one of your other options under 21 CFR 314.110. In the absence of any such action FDA may proceed to withdraw the application. Any amendment should respond to all the deficiencies listed. We will not process a partial reply as a major amendment nor will the review clock be reactivated until all deficiencies have been addressed.

This product may be considered misbranded under the Federal Food, Drug, and Cosmetic Act if it is marketed with these changes prior to approval of this supplemental application.

If you have any questions, please contact:

Mr. Edward Fromm
Regulatory Health Project Manager
(301) 594-5313

Sincerely,

/s/ [Signature]

Robert Temple, M.D.
Director
Office of Drug Evaluation I
Center for Drug Evaluation and Research

DFS
5/10/02

Enclosure

12 pages redacted from this section of
the approval package consisted of draft labeling